The objective was to examine duloxetine 60–120mg/day treatment for relapse prevention in adults with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients who completed open-label phase and were treatment responders (≥50% reduction in Hamilton Anxiety Rating Scale total score to ≤11 and “much”/“very much improved” ratings for the last 2 visits of open-label phase) were randomly assigned to receive duloxetine or placebo for a 26-week double-blind continuation phase. Relapse was defined as ≥2-point increase in illness severity ratings or by discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients (N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P≤0.001) and worsened on each outcome measure (P≤0.001, all comparisons). Duloxetine 60–120 mg/day treatment was efficacious and reduced risk of relapse in patients with GAD.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:26830 |
| Date | January 2008 |
| Creators | Davidson, Jonathan R.T., Wittchen, Hans-Ulrich, Llorca, Pierre-Michel, Erickson, Janelle, Detke, Michael, Ball, Susan G., Russell, James M. |
| Publisher | Technische Universität Dresden |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Source | European Neuropsychopharmacology, Bd.18 (2008), Nr. 9, S. 673–681, ISSN: 0924-977X |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 10.1016/j.euroneuro.2008.05.002 |
Page generated in 0.0024 seconds